Infusion of clinical‐grade enriched regulatory T cells delays experimental xenogeneic graft‐versus‐host disease
暂无分享,去创建一个
P. Delvenne | F. Baron | S. Lucas | L. Seidel | J. Somja | M. Hannon | Y. Beguin | L. Belle | S. Humblet-Baron | C. Lechanteur | P. Drion | E. Baudoux | O. Giet | F. Bruck | A. Chantillon
[1] Helen E. Heslop,et al. Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease , 2013, Haematologica.
[2] F. Baron,et al. Impact of bone marrow-derived mesenchymal stromal cells on experimental xenogeneic graft-versus-host disease. , 2013, Cytotherapy.
[3] Jang-Gi Choi,et al. Long-Term Engraftment of Human Natural T Regulatory Cells in NOD/SCID IL2rγcnull Mice by Expression of Human IL-2 , 2012, PloS one.
[4] F. Baron,et al. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation , 2012, Leukemia.
[5] A. Liston,et al. Immune tolerance: Are regulatory T cell subsets needed to explain suppression of autoimmunity? , 2012, BioEssays : news and reviews in molecular, cellular and developmental biology.
[6] Bruce R. Blazar,et al. Advances in graft-versus-host disease biology and therapy , 2012, Nature Reviews Immunology.
[7] P. Coulie,et al. Demethylation of the FOXP3 gene in human melanoma cells precludes the use of this epigenetic mark for quantification of Tregs in unseparated melanoma samples , 2012, International journal of cancer.
[8] Graham M Lord,et al. A rapid diagnostic test for human regulatory T-cell function to enable regulatory T-cell therapy. , 2012, Blood.
[9] G. Storm,et al. Application of cultured human regulatory T cells requires preclinical in vivo evaluation. , 2012, The Journal of allergy and clinical immunology.
[10] J. Ritz,et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. , 2011, The New England journal of medicine.
[11] J. Ritz,et al. Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. , 2011, Blood.
[12] B. Storer,et al. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. , 2011, Blood.
[13] M. Edinger,et al. Regulatory T cells in stem cell transplantation: strategies and first clinical experiences. , 2011, Current opinion in immunology.
[14] M. Battaglia,et al. Stability of human rapamycin-expanded CD4+CD25+ T regulatory cells , 2011, Haematologica.
[15] R. Negrin,et al. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells. , 2011, Blood.
[16] F. Baron,et al. Regulatory T cells fulfil their promise? , 2011, Immunology and cell biology.
[17] Bruce R. Blazar,et al. Massive ex Vivo Expansion of Human Natural Regulatory T Cells (Tregs) with Minimal Loss of in Vivo Functional Activity , 2011, Science Translational Medicine.
[18] B. Falini,et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. , 2011, Blood.
[19] S. Ziegler,et al. Blood and gastric FOXP3+ T cells are not decreased in human gastric graft-versus-host disease. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[20] R. Storb,et al. Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of age , 2011, Haematologica.
[21] J. Wagner,et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. , 2011, Blood.
[22] R. Porcher,et al. The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation , 2010, Leukemia.
[23] J. Ritz,et al. Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. , 2010, The Journal of clinical investigation.
[24] T. Braun,et al. Frequency of CD4 + CD25 hi FOXP3 + Regulatory T Cells Has Diagnostic and Prognostic Value as a Biomarker for Acute Graft-Versus-Host Disease. , 2009 .
[25] R. Negrin,et al. Rapamycin and IL-2 Prevents Lethal Acute Graft-Versus Host Disease by Expansion of Donor Type CD4+CD25+Foxp3+ Regulatory T Cells. , 2009 .
[26] M. Martelli,et al. Immunomagnetic isolation of CD4+CD25+FoxP3+ natural T regulatory lymphocytes for clinical applications , 2009, Clinical and experimental immunology.
[27] P. Coulie,et al. Comparison of stable human Treg and Th clones by transcriptional profiling , 2009, European journal of immunology.
[28] J. Buckner,et al. Combination of rapamycin and IL-2 increases de novo induction of human CD4(+)CD25(+)FOXP3(+) T cells. , 2008, Journal of autoimmunity.
[29] F. Baron,et al. Evidence for neo-generation of T cells by the thymus after non-myeloablative conditioning , 2008, Haematologica.
[30] J. Dipersio,et al. Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-vs-host disease in NOD/SCID beta2mnull mice. , 2007, Experimental hematology.
[31] L. Verdonck,et al. Human Regulatory T Cells Control Xenogeneic Graft-versus-Host Disease Induced by Autologous T Cells in RAG2−/−γc−/− Immunodeficient Mice , 2006, Clinical Cancer Research.
[32] E. Holler,et al. Isolation of CD4+CD25+ regulatory T cells for clinical trials. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[33] E. Thiel,et al. Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD. , 2006, Blood.
[34] B. Blazar,et al. Acute graft-versus-host disease: from the bench to the bedside. , 2005, Blood.
[35] M. Sorror,et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] R. Storb,et al. Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review , 2004, Springer Seminars in Immunopathology.
[37] E. Warren,et al. The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation. , 2003, Blood reviews.
[38] C. Fathman,et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation , 2003, Nature Medicine.
[39] Catherine J. Wu,et al. Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[40] Sayuri Yamazaki,et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance , 2001, Immunological reviews.
[41] K. Sullivan,et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. , 1981, The New England journal of medicine.
[42] R. Storb,et al. Infusion of donor lymphocytes into stable canine radiation chimeras: implications for mechanism of transplantation tolerance. , 1976, Journal of immunology.
[43] R. Negrin,et al. Natural and expanded CD4(+)CD25(+) regulatory T cells in bone marrow transplantation. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[44] H. Ochs,et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3 , 2001, Nature Genetics.